Surgery Done. Pathological Complete Response.

After everything since November: the diagnosis, the cardiac pause, EC, weekly Taxol, Phesgo, scan after scan. 30 May 2026 was the day we finally got the operation done.

And on 8 June, the pathology report came back with the result we had been hoping for since the first encouraging ultrasound: a pathological complete response (pCR).

---

What surgery involved

The plan had been building for months. By May, the steps looked like this:

• 22 May: Magseed marker inserted (a tiny magnetic seed to guide the surgeon to the right spot)
• 29 May: Sentinel node injection
• 30 May: admission at 06:30 for the main operation

The operation itself was two things on the same day:

1. Therapeutic mammoplasty - removing the area where the cancer had been, but reshaping the breast rather than taking the whole breast (the breast-conserving aim we had discussed with the surgeon back in February)
2. Axillary clearance - removing the lymph nodes from the armpit, which had always been part of the plan because of how extensive the node involvement was at diagnosis

That combination (lumpectomy-style surgery plus a full axillary clearance) is a big day by any measure. But it went ahead as planned.

---

The headline: pCR

Pathology takes a little while. When the report landed on 8 June, the headline was clear:

Pathological complete response.

In plain English: under the microscope, there was no viable invasive breast cancer left in the tissue removed from the breast, and no cancer in any of the 31 lymph nodes examined from the axilla.

The formal scoring puts it simply:

• RCB 0 (Residual Cancer Burden zero, the best category)
• ypT0 ypN0 - no residual tumour in the breast; no involved nodes after treatment

That is the definitive answer chemo and months of imaging could only point towards. Surgery pathology confirmed it.

---

The lymph nodes: zero positive, with a story to tell

0 out of 31 nodes contained cancer.

Four nodes did show signs of regression (essentially scarring and treatment-related change from where cancer had been, not active disease). That fits with what we already knew from scans: the axilla had responded dramatically to chemo long before surgery.

No lymphovascular invasion was seen either - another reassuring line on the report.

---

The one detail worth understanding: the medial margin

Most of the report reads like a victory lap. There is one finding worth explaining properly.

When the pathologist examined an extra shave from the medial (inner) margin (a thin additional sliver of tissue from that edge) - they found a 1.5 mm focus of a cancerised lobule: a small area of cancer-associated changes in a milk-gland unit. Not residual invasive cancer. The main specimen was clear of both DCIS and invasive carcinoma, and that is what drives the pCR call. But a cancerised lobule in a margin shave meant the pathologist wanted to look harder before signing off completely.

The focus sat 3 mm clear of the actual cut edge, which is a meaningful buffer. Still, extra immunostaining was ordered, to to confirm whether the normal protective architecture of that lobule was still intact. We had to sit with “almost confirmed” for a week while the surgeon and pathologist were satisfied.

Confirmed clear (15 June)

The immunostaining came back: p63, SMM, ER, and HER2 all confirmed cancerisation of lobules with no residual DCIS or invasive malignancy. The surgeon called on 16 June with the news, and the drain came out that same morning.

The final diagnosis is unchanged. Excision is complete. pCR stands.

---

The post-op weeks

The first clinic review was 12 June - two weeks after surgery. The wound was healing well, a good shape had been achieved, and arm movement was good (some numbness and strain, which is expected after axillary clearance). The drain was still in at that point, running at around 50 ml per day.

The surgeon confirmed at that visit:

• No further chemotherapy - treatment is done
• Phesgo (antibodies) to continue to complete the full course
• Radiotherapy referral made to the clinical oncology team, with a 15-fraction course recommended over a shorter 5-fraction one, to reduce the risk of breast oedema
• Surgical follow-up booked for 20 November 2026 with a breast ultrasound arranged just beforehand

---

What pCR means for the road ahead

pCR was always the goal on the treatment roadmap sketch from November, the best possible surgical outcome after neoadjuvant chemo for HER2-positive disease.

It does not mean “finished forever.” Phesgo, radiotherapy, and further HER2-targeted treatment decisions still lie ahead, guided by MDT discussion and what pathology shows overall.

But it does mean something concrete and enormous: the treatment worked. The cancer that was biopsied, scanned, and measured for months is, on the evidence of this surgery, gone from the breast and axilla.

After everything, that is a result worth pausing on.